MAGNITUDE CLINICAL TRIAL Trademark

Trademark Overview


On Thursday, March 9, 2023, a trademark application was filed for MAGNITUDE CLINICAL TRIAL with the United States Patent and Trademark Office. The USPTO has given the MAGNITUDE CLINICAL TRIAL trademark a serial number of 97830256. The federal status of this trademark filing is NOTICE OF ALLOWANCE - ISSUED as of Tuesday, June 25, 2024. This trademark is owned by Intellia Therapeutics, Inc.. The MAGNITUDE CLINICAL TRIAL trademark is filed in the Advertising, Business and Retail Services, Computer & Software Services & Scientific Services, and Medical & Beauty Services & Agricultural Services categories with the following description:

Organizing and recruiting patients for clinical trials for the treatment of transthyretin (ATTR) amyloidosis using in vivo gene editing technology

Medical treatment of transthyretin (ATTR) amyloidosis using in vivo gene editing technology

Scientific research in the nature of conducting clinical trials for the treatment of transthyretin (ATTR) amyloidosis using in vivo gene editing technology
magnitude clinical trial

General Information


Serial Number97830256
Word MarkMAGNITUDE CLINICAL TRIAL
Filing DateThursday, March 9, 2023
Status688 - NOTICE OF ALLOWANCE - ISSUED
Status DateTuesday, June 25, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, April 30, 2024

Trademark Statements


Description of MarkThe mark consists of the word "MAGNITUDE" in red-orange, with the words "CLINICAL TRIAL" in gray appearing below the wording and a stylized design of the sun appearing above in shading from red-orange at the top to orange to yellow at the bottom.
Indication of Colors claimedThe color(s) red-orange, orange, yellow and gray is/are claimed as a feature of the mark.
Goods and ServicesOrganizing and recruiting patients for clinical trials for the treatment of transthyretin (ATTR) amyloidosis using in vivo gene editing technology
Goods and ServicesMedical treatment of transthyretin (ATTR) amyloidosis using in vivo gene editing technology
NOT AVAILABLE"CLINICAL TRIAL"
Goods and ServicesScientific research in the nature of conducting clinical trials for the treatment of transthyretin (ATTR) amyloidosis using in vivo gene editing technology

Classification Information


International Class035 - Advertising; business management; business administration; office functions.
US Class Codes100, 101, 102
Class Status Code6 - Active
Class Status DateFriday, February 23, 2024
Primary Code035
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateWednesday, March 29, 2023
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateWednesday, March 29, 2023
Primary Code044
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameIntellia Therapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressCambridge, MA 02139

Party NameIntellia Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCambridge, MA 02139

Trademark Events


Event DateEvent Description
Saturday, December 23, 2023EXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED
Saturday, December 23, 2023COMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION AUTOMATIC ENTRY
Saturday, December 23, 2023EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
Saturday, December 23, 2023NOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
Friday, February 23, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, March 13, 2023NEW APPLICATION ENTERED
Wednesday, March 29, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, March 30, 2023NOTICE OF DESIGN SEARCH CODE E-MAILED
Thursday, December 7, 2023ASSIGNED TO EXAMINER
Friday, February 23, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, February 23, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, March 22, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, April 10, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 30, 2024PUBLISHED FOR OPPOSITION
Tuesday, April 30, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 25, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT